EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Theranexus's enterprise value is €6.94 Mil.
Theranexus's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil. Therefore, Theranexus's EV-to-Revenue for today is .
The historical rank and industry rank for Theranexus's EV-to-Revenue or its related term are showing as below:
XPAR:ALTHX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.075 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-04), Theranexus's stock price is €1.05.
Theranexus's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Therefore, Theranexus's PS Ratio for today is .
Theranexus EV-to-Revenue Historical Data
The historical data trend for Theranexus's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Theranexus's EV-to-Revenue
For the Biotechnology subindustry, Theranexus's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theranexus's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theranexus's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Theranexus's EV-to-Revenue falls into.
Theranexus's current Enterprise Value is €6.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Theranexus's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theranexus's share price for today is €1.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theranexus EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Theranexus's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XPAR:ALTHX has been successfully added to your 